Lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Huntington's disease has autosomal dominant inheritance, meaning that an affected individual typically inherits one copy of the gene with an expanded trinucleotide repeat (the mutant allele) from an affected parent. Since the penetrance of the mutation is very high, those who have a mutated copy of the gene will have the disease. In this type of inheritance pattern, each offspring of an affected individual has a 50% risk of inheriting the mutant allele and developing the disease (see figure). This probability is sex-independent since the huntingtin gene is not located on the X or Y chromosomes. Trinucleotide CAG repeats numbering over 28 are unstable during replication, and this instability increases with the number of repeats present. This usually leads to new expansions as generations pass (dynamic mutations) instead of reproducing an exact copy of the trinucleotide repeat. This causes the number of repeats to change in successive generations, such that an unaffected parent with an "intermediate" number of repeats (28–35), or "reduced penetrance" (36–40), may pass on a copy of the gene with an increase in the number of repeats that produces fully penetrant HD. The earlier age of onset and greater severity of disease in successive generations due to increases in the number of repeats is known as genetic anticipation. Instability is greater in spermatogenesis than oogenesis; maternally inherited alleles are usually of a similar repeat length, whereas paternally inherited ones have a higher chance of increasing in length.
Score 0: There is no need for periodontal treatment. Score 1: Provide patient with Oral hygiene instruction (OHI). Score 2: Provide patient with Oral hygiene instruction (OHI) and remove plaque retentive factors, including all supra- and subgingival calculus and any restoration overhangs. Score 3: Provide patient with Oral hygiene instruction (OHI) and root surface debridement (RSD). Score 4: Provide patient with Oral hygiene instruction (OHI) and root surface debridement (RSD). In addition, patient should be evaluated for the requirement of more complex treatment. A referral to specialists may be needed.
Emotional dysregulation is a core feature of BPD and it is characterized by a difficulty in effectively managing emotional states. It may involve high sensitivity to emotional stimuli, heightened emotional intensity, large and rapid mood shifts, tendency for negative emotions, high affective empathy but low cognitive empathy, and a slow return to baseline after emotional arousal. Emotional dysregulation extends beyond emotions, affecting cognition, relationships, and behavior. Deficits in emotion regulation strategies are observed in BPD. These include resistance to accepting emotional responses, low flexibility to changing strategies, difficulty in identifying emotions, as well as a deficit in goal-directed behavior, and in using healthy coping strategies. Maladaptive strategies commonly used to regulate their emotions include self-harm, rumination, avoidance, and thought suppression. Emotional dysregulation is thought to be caused by an imbalance in the limbic system and the prefrontal cortex, particularly in the amygdala. Dialectical behavior therapy can be employed to help with emotional dysregulation.
=== Excretion === A few minutes after ingestion, strychnine is excreted unchanged in the urine, and accounts for about 5 to 15% of a sublethal dose given over 6 hours. Approximately 10 to 20% of the dose will be excreted unchanged in the urine in the first 24 hours. The percentage excreted decreases with the increasing dose. Of the amount excreted by the kidneys, about 70% is excreted in the first 6 hours, and almost 90% in the first 24 hours. Excretion is virtually complete in 48 to 72 hours.
=== Books === Boitano, Scott; Brooks, Heddwen L.; Barman, Susan M.; Barrett, Kim E. (2016). Ganong's Review of Medical Physiology. McGraw-Hill Education. ISBN 978-0-07-182510-8. Susan Standring, ed. (2008). Gray's anatomy: the anatomical basis of clinical practice (40th ed.). London: Churchill Livingstone. ISBN 978-0-8089-2371-8. Cole, Laurence A.; Kramer, Peter R. (2016). Human Physiology, Biochemistry and Basic Medicine. Amsterdam: Academic Press. ISBN 978-0-12-803699-0.
Sources: en.wikipedia.org
=== Phase unknown === AST-004 – adenosine A1 and A3 receptor agonist – migraine [35] Propofol hemisuccinate (EP-102; EP-103) – GABAA receptor positive allosteric modulator (propofol prodrug) – migraine [36] Topiramate oral suspension – various actions – migraine [37]
== Alternative carbon fixation pathways == RuBisCO is important biologically because it catalyzes the primary chemical reaction by which inorganic carbon enters the biosphere. While many autotrophic bacteria and archaea fix carbon via the reductive acetyl CoA pathway, the 3-hydroxypropionate cycle, or the reverse Krebs cycle, these pathways are relatively small contributors to global carbon fixation compared to that catalyzed by RuBisCO. Phosphoenolpyruvate carboxylase, unlike RuBisCO, only temporarily fixes carbon. Reflecting its importance, RuBisCO is the most abundant protein in leaves, accounting for 50% of soluble leaf protein in C3 plants (20–30% of total leaf nitrogen) and 30% of soluble leaf protein in C4 plants (5–9% of total leaf nitrogen). Given its important role in the biosphere, the genetic engineering of RuBisCO in crops is of continuing interest (see below).
Because β-alanine dipeptides are not incorporated into proteins, they can be stored at relatively high concentrations. Occurring at 17–25 mmol/kg (dry muscle), carnosine (β-alanyl-L-histidine) is an important intramuscular buffer, constituting 10-20% of the total buffering capacity in type I and II muscle fibres. In carnosine, the pKa of the imidazolium group is 6.83, which is ideal for buffering.
The Chinese Nationalist Air Force obtained the P-51 during the late Sino-Japanese War to fight against the Japanese. After the war, Chiang Kai-shek's Nationalist government used the planes against insurgent Communist forces. The Nationalists retreated to Taiwan in 1949. Pilots supporting Chiang brought most of the Mustangs with them, where the aircraft became part of the island's defense arsenal. People's Republic of China
== Criticism == The PSI has received notable criticism from the structural biology community. Among these charges is that the main product of the PSI – PDB files of proteins' atomic coordinates as determined by X-ray crystallography or NMR spectroscopy – are not useful enough to biologists to justify the project's $764 million cost. Critics note that money currently spent on the PSI could have otherwise funded what they consider worthier causes:
Sources: en.wikipedia.org
== Further reading == Banting, F.G. & Best, C.H. (1922), "The Internal Secretions of the Pancreas", The Journal of Laboratory and Clinical Medicine, Vol.7, No.5, (February 1922), pp. 251–266. Banting, F.G., Best, C.H., Collip, J.B., Campbell, W.R. & Fletcher, A.A. (1922), "Pancreatic Extracts in the Treatment of Diabetes Mellitus", The Canadian Medical Association Journal, Vol.12, No.3, (March 1922), pp.141–146. US patent no.1,469,994 (held by "Frederick G. Banting and Charles Herbert Best, of Toronto, Ontario, and James Bertram Collip of Edmonton, Alberta, Canada"), (filed: 12 January 1923), (patented: 9 October 1923), for "Extract Obtainable from the Mammalian Pancreas or from the Related Glands in Fishes, Useful in the Treatment of Diabetes Mellitus, and a Method of Preparing it". Henry B. M. Best (2003). Margaret and Charley: The Personal Story of Dr. Charles Best, the Co-Discoverer of Insulin. Dundurn Press Ltd. ISBN 1-55002-399-3. John Waller (2002) Fabulous Science: fact and fiction in the history of scientific discovery, Oxford. See Chapter 11: "Painting yourself into a corner; Charles Best and the discovery of insulin", page 223.
Yemelyan Pugachev, a low-status Don Cossack, arrived in the Yaik Host in late 1772. There, he claimed to be Peter III, playing on the Cossack belief that Peter would have been an effective ruler but for his assassination in a plot by his wife, Catherine II. Many Yaik Cossacks believed Pugachev's claim, although those closest to him knew the truth. Others, who may have known of it, did not support Catherine II due to her disposal of Peter III, and also spread Pugachev's claim to be the late emperor. The first of three phases of Pugachev's Rebellion began in September 1773. Most of the rebels' first prisoners were Cossacks who supported the elite. After a five-month siege of Orenburg, a military college became Pugachev's headquarters. Pugachev envisioned a Cossack tsardom, similar to Razin's vision of a united Cossack republic. The peasantry across Russia stirred with rumors and listened to the manifestos Pugachev issued. But the rebellion soon came to be seen as an inevitable failure. The Don Cossacks refused to help the final phase of the revolt, knowing that military troops were closely following Pugachev after lifting the siege of Orenburg, and following his flight from defeated Kazan. In September 1774, Pugachev's own Cossack lieutenants turned him over to the government troops. Opposition to centralization of political authority led the Cossacks to participate in Pugachev's Rebellion. After their defeat, the Cossack elite accepted government reforms, hoping to secure status within the nobility.
The pentose phosphate pathway (also called the phosphogluconate pathway and the hexose monophosphate shunt and abbreviated as PPP) is a metabolic pathway parallel to glycolysis. It generates NADPH and pentoses (five-carbon sugars) as well as ribose 5-phosphate, a precursor for the synthesis of nucleotides. While the pentose phosphate pathway does involve oxidation of glucose, its primary role is anabolic rather than catabolic. The pathway is especially important in red blood cells (erythrocytes). The reactions of the pathway were elucidated in the early 1950s by Bernard Horecker and co-workers. There are two distinct phases in the pathway. The first is the oxidative phase, in which NADPH is generated, and the second is the non-oxidative synthesis of five-carbon sugars. For most organisms, the pentose phosphate pathway takes place in the cytosol; in plants, most steps take place in plastids. Like glycolysis, the pentose phosphate pathway appears to have a very ancient evolutionary origin. The reactions of this pathway are mostly enzyme catalyzed in modern cells, however, they also occur non-enzymatically under conditions that replicate those of the Archean ocean, and are catalyzed by metal ions, particularly ferrous ions (Fe(II)). This suggests that the origins of the pathway could date back to the prebiotic world.
The preparation of THC was reported in JACS in 1965. That procedure called for the intramolecular alkyl lithium attack on a starting carbonyl to form the fused rings, and a tosyl chloride mediated formation of the ether.
A DNA vaccine is a type of vaccine that transfects a specific antigen-coding DNA sequence into the cells of an organism as a mechanism to induce an immune response. DNA vaccines work by injecting genetically engineered plasmid containing the DNA sequence encoding the antigen(s) against which an immune response is sought, so the cells directly produce the antigen, thus causing a protective immunological response. DNA vaccines have theoretical advantages over conventional vaccines, including the "ability to induce a wider range of types of immune response". Several DNA vaccines have been tested for veterinary use. In some cases, protection from disease in animals has been obtained, in others not. Research is ongoing over the approach for viral, bacterial and parasitic diseases in humans, as well as for cancers. In August 2021, Indian authorities gave emergency approval to ZyCoV-D. Developed by Cadila Healthcare, it is the first DNA vaccine approved for humans.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.